Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095548 | 0.83 | ACACB (0.57) | ACACBTNFNOD2NOD1KMT2A | |
| SCHEMBL6962643 | 0.82 | ACACB (0.51) | ACACBTNFNOD2NOD1KMT2A | |
| SCHEMBL2093709 | 0.80 | ACACB (0.59) | ACACBTNFNOD2NOD1KMT2A | |
| SCHEMBL14234932 | 0.80 | TNF (0.67) | TNFNOD2NOD1KMT2AMEN1 | |
| SCHEMBL3161336 | 0.79 | ACACB (0.57) | ACACBTNFNOD2NOD1KMT2A | |
| SCHEMBL27624902 | 0.79 | DHCR7 (0.60) | ACACBTNFNOD2NOD1KMT2A | |
| SCHEMBL10677884 | 0.78 | ABCB1 (0.56) | ACACBTNFNOD2NOD1KMT2A | |
| SCHEMBL3152306 | 0.77 | ACACB (0.55) | ACACBDRD4SIGMAR1DRD2ABCB1 | |
| SCHEMBL23774387 | 0.74 | ACACB (0.69) | ACACBTNFNOD2NOD1KMT2A | |
| SCHEMBL3156676 | 0.73 | ACACB (0.51) | ACACBTNFNOD2NOD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | ACACB 881/4885TNF 3236/4885NOD2 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.